Atalanta Therapeutics Announces Leadership Transitions

BOSTON--(BUSINESS WIRE)-- Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of intractable neurological diseases, announced today that Joanne Kotz has been named Chief Executive Officer and a member of the Board of Directors, succeeding Alicia Secor, who has stepped down as part of a planned transition to pursue other opportunities. The company also announced the appointment of Douglas Pagán as Chief Financial Officer & Chief Operating Officer, succeeding Jeffrey Young.
Additionally, Bob D. Brown, an industry veteran with extensive RNAi drug discovery and development experience, has joined the company's Scientific Advisory Board to advise as the company advances its innovative pipeline into the clinic.
"I want to thank Alicia for her extraordinary leadership of the company from formation to the cusp of entry into the clinic, as well as her continued role as an advisor through this transition,' said Dr. Stephen Knight, President and Senior Managing Partner of F-Prime and a member of the Atalanta Board of Directors. 'We are delighted to have Joanne lead Atalanta's next stage. Joanne is an accomplished leader who has demonstrated the ability to advance innovative platforms and pipelines through the transition to clinical stage, and has optimized company value creation through strong financings, partnerships and strategic transactions.'
'I'm thrilled to be joining Atalanta, which is pioneering the effort to bring RNAi therapies to patients living with devastating neurological diseases,' said Dr. Kotz. 'I am passionately committed to Atalanta's mission to deliver life-transforming therapies to patients and look forward to working with the team to transition our first programs into the clinic as we work to realize the full therapeutic potential of Atalanta's innovative di-siRNA platform.'
'Over the past six years we've made incredible scientific progress at Atalanta. I'm proud of all that we've been able to accomplish together and thank the Board and team for their support and dedication to our mission,' said Ms. Secor. 'The transition from research to clinical stage is a critical time for any biotech, and Joanne's leadership and experience is ideally suited to guide Atalanta's continued progress towards our mission of delivering RNAi medicines to patients living with severe neurological diseases.'
Dr. Kotz brings to Atalanta extensive executive experience, including most recently as cofounder and CEO of Jnana Therapeutics. She led the company from an early discovery platform stage through the transition to clinical stage. Jnana was acquired by Otsuka Pharmaceutical in 2024 for ~$1 billion following the demonstration of positive clinical proof of concept for the company's lead rare disease program. Prior to Jnana, Dr. Kotz held leadership roles at FBRI, F-Prime Capital's initiative to enable therapeutic breakthroughs in Alzheimer's disease and related brain disorders, and at the Broad Institute. She is a member of the Board of Directors of the Chordoma Foundation. Dr. Kotz received her Ph.D. in chemistry from the University of California, Berkeley and a B.S. in chemistry from the University of Florida. She conducted postdoctoral research at Genentech and at the Necker Children's Hospital in Paris.
Mr. Pagán brings to Atalanta more than two decades of experience in finance, investor relations, and capital formation across both public and venture-backed biopharmaceutical companies. Prior to joining Atalanta, he served as Chief Financial Officer and Chief Operating Officer at Jnana Therapeutics, where he was instrumental in securing the company's $107 million Series C financing heading into the clinic, and the subsequent ~$1 billion acquisition by Otsuka Pharmaceutical. Prior to Jnana, Mr. Pagán was Chief Financial Officer at the RNAi company Dicerna Pharmaceuticals, where he oversaw the 2021 sale of the company to Novo Nordisk for $3.3 billion. He has previously held leadership roles at Acceleron and Biogen and has served on the Board of Directors of the biotech companies Ziopharm Oncology and Timberlyne Therapeutics. Mr. Pagán holds an MBA from Columbia Business School and a BSE in chemical engineering from Princeton University.
Dr. Brown brings more than 30 years of experience in RNAi and oligonucleotide research and development, including from discovery through drug approval and across a wide range of clinical indications and regulatory jurisdictions. Most recently, Dr. Brown served as Chief Scientific Officer and Executive Vice President of R&D at Dicerna Pharmaceuticals, an RNAi-focused therapeutics company that was acquired by Novo Nordisk. At Novo, he served as President and Head of the Dicerna Transformation Research Unit and SVP. Prior to Dicerna, Dr. Brown held various R&D leadership positions at Genta, a clinical-stage antisense oligonucleotide therapeutics company, and previously was a co-founder of Oasis Biosciences, which was acquired by Gen-Probe. Dr. Brown earned a Ph.D. in molecular biology from the University of California, Berkeley and B.S. degrees in chemistry and biology from the University of Washington, Seattle.
About Atalanta Therapeutics
Atalanta Therapeutics is a biotechnology company developing treatments for intractable diseases of the central nervous system using RNA interference. Atalanta's unique platform of divalent small interfering RNA (di-siRNA) is designed to enable durable, selective gene silencing throughout the brain and spinal cord. Atalanta is advancing a wholly owned pipeline of disease-modifying programs for Huntington's disease, genetic epilepsy, severe chronic pain, and other neurological diseases in addition to partnered programs as part of a strategic collaboration with Genentech. Atalanta is headquartered in Boston, Mass. For more information, visit www.atalantatx.com.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Wire

4 hours ago

• Business Wire

GE HealthCare drives innovation in theranostics with latest technological advances

CHICAGO--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processing i – an AI-powered innovation to help aid physician decision making and therapy response monitoring. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief Share With cancer accounting for over 10 million deaths globally each year, ii the rise of precision care – particularly theranostics – is offering new hope to patients. By combining advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, theranostics enables a personalized, patient-centric approach that may help improve disease detection, treatment accuracy, and overall quality of life. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. 'With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry—ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives.' Central to the practice of theranostics is molecular imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which provides detailed, patient-specific insights to guide and monitor treatment. However, accessing these insights – like whole-body tumor burden, which represents the total amount of cancer is in the body – has traditionally required time-consuming manual analysis, resulting in clinical and operational challenges. In response, GE HealthCare's MIM Software is introducing LesionID Pro with automated zero-click pre-processing, i designed with AI-powered automation to help physicians access reliable whole-body tumor burden statistics without having to spend hours manually segmenting lesions, removing normal physiologic uptake, and registering multiple patient images for comparison. In addition to turning manual pre-processing into a zero-click experience, this new version of LesionID Pro comes with significant algorithm improvements that provide physicians with a precise whole-body tumor volume to review and finalize. Intuitive, user-friendly tools were intentionally designed with input from leading theranostics practitioners with the ultimate goal of making whole-body tumor burden analysis a practical clinical reality and help shorten physicians' time-to-report. 'At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics,' shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. 'We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient's entire care journey – from the imaging equipment needed for a noninvasive look at a patient's anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes.' Also on display at #SNMMI25, as part of GE HealthCare's comprehensive portfolio of theranostics-enabling solutions for clinical and operational excellence, are the following innovations: MINItrace Magni, iii GE HealthCare's newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans. Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities. Omni Legend is a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands by enabling clinicians to reduce dose by up to 40% iv while maintaining exceptional image quality. Supportive of the diagnostic portion of theranostics, the system continues to gain in popularity, representing the company's fastest-ever-selling PET/CT. v StarGuide is a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system is designed to help clinicians pinpoint the size, shape, and position of lesions and monitor therapy with exceptional precision. Its flexibility in patient scanning and workflow efficiencies also support high patient throughput and help reduce complexity. For oncology patients, especially those in pain, short scans can help enhance comfort and overall experience. Aurora is an advanced dual-head SPECT/CT designed with excellent diagnostic capabilities vi and streamline workflows, offering clinicians excellent image quality and operational efficiency. Its CT has a 40 mm detector – twice the detector coverage compared to CTs of other hybrid systems vii – with the ability to reduce the dose up to 82%, viii support accurate quantitation, and help clinicians make the personalized care decisions that are at the heart of theranostics. Theranostics Pathway Manager Tile is an easy-to-use application, available on GE HealthCare's Command Center software, that is designed to simplify the time-consuming task of coordinating the theranostics care pathway. It does so by tracking patient readiness for therapy, eliminating the need for manual data gathering across disparate systems (e.g., labs, scheduling, ordering, spreadsheets), and providing a unified, up-to-date view of each patient's treatment journey. Oregon Health & Science University will be an early adopter. 'Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care,' says Erik Mittra, M.D., Ph.D., professor of diagnostic radiology in the at Oregon Health & Science University. Altogether, GE HealthCare has the unique ability to provide solutions along every step of the theranostics care pathway. Our integrated portfolio of solutions provides clinicians with the isotopes, imaging, informatics, and molecular imaging agents necessary for the practice and advancement of precision care. For more information on GE HealthCare's innovative portfolio of theranostics-enabling solutions, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. i LesionID Pro with automated zero-click pre-processing is 510(k)-pending with the U.S. FDA. Not CE Marked and not licensed in accordance with Canadian law. Not available for sale in the United States, Europe, Canada, or any other region. ii Cancer. World Health Organization. Published February 3, 2022. Accessed March 2, 2023. iii Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE marked. iv Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing. v Based on orders data of GE HealthCare PET/CT systems since 2010. vi Compared to NM/CT 870 DR. vii As compared to NM/CT 870 DR with Optima 540 CT. viii a ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability). viii b In clinical practice, the use of ASiR‐V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR‐V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method.

Business Insider

6 hours ago

• Business Insider

It's not just for gyms bros — scientists say a 50-cent muscle-building supplement slows aging and may counteract Alzheimer's

Creatine — long beloved by gym rats who mix it into protein shakes — is shaping up to be much more than a muscle building and fat loss supplement. Mounting research suggests it may also boost heart health, protect against Alzheimer's, improve mood, and strengthen your bones. While researchers typically have a healthy mistrust of supplements, creatine is the rare exception, recommended even among skeptical scientists and doctors: it's reliably safe, relatively inexpensive, and backed by extensive, high-quality studies. And it costs, on average, less than 50 cents per serving. "I don't know if there's anything on the planet that comes close to creatine from a multifactorial approach," Darren Candow, a top creatine researcher and professor of exercise physiology, nutrition and aging at Regina University in Canada, told Business Insider. Over the past decade, interest in creatine has skyrocketed, in tandem with research showing it can double up as a longevity supplement. As of May, the US creatine market is worth $456.6 million, up 36% from the prior year, according to data and analytics company Spins. "As much as we can define a longevity supplement at this point, creatine is probably one of the best in that category," Jordan Glen, supplement researcher and chief science officer for health startup SuppCo., an app that helps users find the right supplements for their goals, told Business Insider. Creatine drives your muscles to push harder without getting tired Creatine was first discovered in muscle tissue in 1832. Nearly a century later, scientists started to figure out how it's stored and used for energy in the human body. They experimented with extracting creatine from meat and later synthesizing it in a lab. But it wasn't until the Barcelona Olympic Games in 1992 that creatine went mainstream. The British gold-medal sprinters, sharing how they got in shape, gushed about the powerful effects of a little-known supplement: creatine. In 1993, the first commercial creatine hit store shelves, and sales boomed. Creatine is a raw material for producing ATP, a molecule that gives our cells energy. The majority of creatine is stored in the muscles, where it offers a ready fuel source for high-intensity effort. More creatine can improve strength and muscle gains by providing a bit more energy, helping you push a little bit harder and work out for longer before getting tired. Our bodies naturally produce creatine through a combination of amino acids. That's only a small amount, though. We can get more of it from some foods like red meat and fish — or, through supplements. In the past five years, demand for creatine as a fitness aid has spiked, with retail prices up 150% and sales increased by 90% year over year, despite steadily rising costs. And it's not just for muscle-hungry gym bros. While men continue to make up the majority of creatine users, about 21% of the creatine buyers are women, according to data from nationwide supplement retailers The Vitamin Shoppe. At SuppCo, both Glen, the CSO, and Steve Martocci, the CEO, said their wives have recently started taking creatine — reflecting a broader trend of women as a growing consumer base. What changed? Martocci pointed to more evidence dispelling the myth that creatine is just for muscle men to bulk up. Plus, early research suggests creatine can support hormonal health for women, helping to counteract shifts that can occur during the menstrual cycle by helping to maintain levels of glycogen in the muscle for better energy and performance. Creatine slows aging and boosts brain health, per new research In June, a small study found that patients with Alzheimer's disease saw a boost to their cognitive function after supplementing creatine. "We think that just providing more energy to the brain could be useful," Scott Forbes, a sports science researcher and professor at Brandon University who was not involved in the study, told Business Insider. "The brain actually uses about 20% of your total energy expenditure, even though it only weighs about 2% of your body weight. So for a tissue, it's very energetically demanding," Forbes said. Creatine also seems to have an anti-inflammatory effect, making the brain more resilient against stresses that would wear down its ability to perform. "We know that too much inflammation or too much oxidative stress can also lead to poor cognition or poor brain functions," Forbes said. Other recent studies have found that supplementing creatine could also help to mitigate the effects of aging or a concussion. "The theory is that the brain can remodel itself or at least maintain its function during times of stress," Candow, the aging researcher at Regina University, told Business Insider. "I don't know anybody in the world that's not stressed." The new research is expanding creatine's reach to consumers beyond the gym, according to Muriel Gonzalez, president of nationwide supplement retailer The Vitamin Shoppe. "Creatine is undergoing a major transformation — from a niche sports nutrition supplement to a versatile tool for daily health and longevity," Gonzalez told Business Insider over email. Total creatine sales have spiked by 300% from 2019 to 2024 at The Vitamin Shoppe, and are continuing to grow at a double-digit pace, according to company data. Should you be taking creatine? You'll be disappointed if you expect to transform your life, and health, with a few doses of creatine. A supplement can provide a boost but ultimately makes a relatively small difference. Your overall diet, exercise, and lifestyle are far more important. Still, the bottom line is that more and more research supports taking creatine for a huge range of benefits, with very little downside. "I think almost everybody should consider taking creatine," Forbes, the science researcher at Brandon University, said. Even in high doses over a long time period, side effects are mild, such as gastrointestinal upset and a slight increase in water retention, since creatine pulls water into the muscles. "Overall it's one of the safest supplements out there," Eric Gonzalez, a neuroscience professor at Texas Christian University who has studied creatine, told Business Insider. "If anyone wants to go on a supplement, creatine won't hurt you, there's only going to be an upside." If you're losing weight — including those on a GLP-1 drug that triggers weight loss — creatine can help you retain muscle mass, promoting a higher ratio of muscle to body fat. For those looking to boost brain health or mood, early studies suggest that 10-30 grams a day may be beneficial. Glen previously conducted research on senior Olympians who took creatine and found it helped them get stronger and faster while avoiding age-related decline. "We're never too old to take creatine," he said.

13 hours ago

Diabetes drug may cut migraine days in half with little weight loss: Study

Drugs in the same family as Ozempic and Wegovy are known for treating diabetes and helping with weight loss, but a small, early-stage study suggested they might also ease migraines -- even when there's no weight loss. The benefit appears to come from lowering pressure in the brain, Dr. Simone Braca, a neurologist at the University of Naples Federico II and lead author of the study, explained to ABC News. 'This study is very interesting in that the GLP 1s are hypothesized to lower brain pressure, which can then lower your chance of getting a headache or a migraine,' Braca said. The small, 12-week study tracked 26 adults with obesity who had chronic or frequent migraines. Published in Headache -- the official journal of the American Headache Society -- and presented at this week's European Academy of Neurology meeting in Finland, it tested liraglutide, a type of GLP-1 drug commonly used for diabetes and weight loss. After taking a daily 1.8 mg dose of liraglutide for three months -- the amount typically used to treat diabetes -- their average number of headache days per month dropped from 20 to about nine. Participants also reported less disability from migraines, with scores on a standard headache impact scale cut by more than half. Although some participants lost a small amount of weight, Braca said the few lost pounds were not meaningful enough to explain the improvement in migraines. Instead, Braca pointed to pressure from cerebrospinal fluid -- the liquid that surrounds and cushions the brain and spine. He said he believes that even slight buildups of this fluid can press on nearby veins and nerves in the brain, potentially triggering migraines. 'An increased pressure of the spinal fluid in the brain may be one of the mechanisms underlying migraine,' Braca said. 'And if we target this mechanism, this preliminary evidence suggests that it may be helpful for migraine.' Nearly half of patients reported at least a 50% reduction in headache days, according to the Headache paper. About 40% experienced mild side effects like nausea or constipation. None stopped taking the medication. With such promising results, Braca and his research team, led by Dr. Roberto De Simone, are already planning larger trials. Future studies will measure brain pressure more directly and explore whether other GLP 1 drugs might also offer the same relief but with fewer side effects. 'There are still a substantial portion of migraine patients that face an unmet need and that live with its burden,' he said. 'New drugs that could target other pathways, I think that could be reassuring to those patients and give them hope.' The study adds to growing evidence that GLP-1 drugs may have benefits beyond diabetes and weight loss. Researchers are already studying these medications for a range of other conditions, including reducing the risk of heart disease and stroke, easing symptoms of addiction and treating Alzheimer's disease.